A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Body

Solid Tumors Clinical Trial

Official title:

An Open Label, 2 Period, Fixed-sequence Study to Assess the Effect of Savolitinib on the Pharmacokinetics of Oral Midazolam (a CYP450 3A Probe) in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04187456
• Other study ID #: D5084C00004
• Status: Completed
• Phase: Phase 1
• Start date: December 27, 2019
• Est. completion date: March 6, 2020

Study information

• Verified date: August 2020
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will be an open label, 2 period, fixed sequence study in healthy male subjects, performed at a single study center in the Unites States of America. The purpose of this study is to evaluate the effect of savolitinib on the PK of midazolam, a known cytochrome P450 (CYP) 3A substrate.

Description:

This study is designed as an open-label, 2 treatment period, fixed sequence study in healthy male subjects, performed at a single study center. The study will comprise: - A screening period of maximum 28 days; - Two treatment periods: Treatment Period 1 consists of 5 days (Study Days -1 to 4), starting with admission to the Study Center on Study Day -1, dosing of midazolam alone on Study Day 1 and ending on Study Day 4, after a 3 day washout period. Treatment Period 2 consists of 2 days (Study Days 5 and 6), with administration of midazolam in combination with savolitinib on Study Day 5. Subjects will be discharged from the Study Center on Study Day 6, after the last PK sample is collected. - The Follow up Visit will occur at least 14 days (Study Day 19 or after) after the administration of savolitinib in Treatment Period 2. - Subjects will be admitted to the Study Center on Study Day -1, prior to the evening meal the night before dosing with midazolam alone (Study Day 1) and will stay in house until at least 24 hours after dosing with midazolam in combination with savolitinib (Study Day 5). Subjects will thus be discharged on Study Day 6, after the last PK sample has been collected. Each subject will be involved in the study between 21 and approximately 48 days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 14
• Est. completion date: March 6, 2020
• Est. primary completion date: March 6, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Provision of signed and dated, written informed consent prior to any study specific procedures.

2. Healthy male subjects, aged 18 - 65 years (inclusive) , with suitable veins for cannulation or repeated venipuncture.

3. Have a body mass index (BMI) between 18 and 35 kg/m2 inclusive and body weight greater than 50 kg and no more than 100 kg.

4. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and Total Bilirubin (TBL) less than or equal to upper limit of normal for the institution at screening.

5. Have a calculated creatinine clearance (CrCL) greater than 80 mL/min using the Cockcroft-Gault formula at screening.

6. Provision of a signed, written and dated informed consent for optional genetic/biomarker research. If a subject decline to participate in the genetic component of the study, there will be no penalty or loss of benefit to the subject. The subject will not be excluded from other aspects of the study described in the protocol..

Exclusion Criteria:

1. Healthy subjects of Japanese ethnicity and any healthy subject that has 1 parent or grandparent (maternal or paternal) of Japanese ethnicity.

2. History of any clinically significant disease or disorder which, in the opinion of the PI, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study.

3. History or presence of gastrointestinal (GI), hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.

4. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of IMP.

5. Planned in-patient surgery, dental procedure or hospitalizing during the study.

6. Any clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results, as judged by the PI.

7. Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV) antibody.

8. Abnormal vital signs, after 5 minutes supine rest, defined as any of the following:

(1) Systolic BP < 90 mmHg or = 140 mmHg (2) Diastolic BP < 50 mmHg or = 90 mmHg (3) Heart rate < 45 or > 85 beats per minute. 9 Any clinically significant abnormalities in rhythm, conduction or morphology of the 12-lead resting ECG that may interfere with the interpretation of QTc interval changes.

These include healthy subjects with any of the following:

1. Abnormal ST-T-wave morphology, particularly in the protocol defined primary lead (V2) or left ventricular hypertrophy.

2. PR interval shortening < 120 ms (PR > 110 ms but < 120 ms is acceptable if there is no evidence of ventricular pre-excitation).

3. PR interval prolongation (> 200 ms). Intermittent second (Type 1 second degree block [Wenckebach Phenomenon] while asleep is not exclusive) or third degree atrioventricular (AV) block, or AV dissociation.

4. Persistent or intermittent complete bundle branch block (BBB), incomplete bundle branch block (IBBB), or intraventricular conduction delay (IVCD) with QRS > 110 ms. Subjects with QRS > 110 ms but < 115 ms are acceptable if there is no evidence of e.g., ventricular hypertrophy or pre-excitation.

5. Mean resting correct QT interval (QTcF) > 450 ms for men on screening obtained from 3 ECGs or history or factors that may increase the risk of QTcF prolongation such as chronic hypokalemia not correctable with supplements, congenital or familial long QT syndrome, or family history of unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsade de Pointes (TdP). 10 Known or suspected history of drug abuse, as judged by the Principal Investigator. 11 Current smokers or those who have smoked or used nicotine products within the previous 30 days. 12 History of alcohol abuse, as judged by the PI, or excessive intake of alcohol (defined as an average weekly intake of > 21 units or an average daily intake of > 3 units). 13 Excessive intake of caffeine-containing drinks or food (e.g., coffee, tea, chocolate) as judged by the Investigator. 14 Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks prior to the administration of IMP. 15 Any intake of grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade, or other products containing grapefruit or Seville oranges within 7 days of the firs admission on Day -1. 16 Use of any prescribed or non-prescribed medication including antacids, analgesics (other than use of ibuprofen) up to 72 hours before first dosing day until final follow-up visit, herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of IMP or longer (5 times half-life) if the medication has a long half-life. 17 Positive screen for drugs of abuse, cotinine (nicotine) and/or alcohol at screening and at admission to the Study Center and/or positive screen for alcohol on admission to the Study Center (Day -1, Treatment Period 1). 18 History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the PI or history of hypersensitivity to drugs with a similar chemical structure or class to savolitinib or midazolam. 19 Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening. 20 Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the administration of IMP in this study. The period of exclusion begins 3 months after the final dose or one month after the last visit, whichever is the longest. Note: subjects consented and screened, but not randomized in this study or a previous phase I study, are not excluded. 21 Known or suspected history of alcohol abuse or excessive intake of alcohol as judged by the PI. 22 Involvement of any AstraZeneca, Parexel or study site employee or their close relatives. 23 Subjects who have previously received savolitinib or midazolam. 24 Judgement by the PI that the subject should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements. 25 Subjects who are vegans, vegetarians or have medical dietary restrictions and who are lactose intolerant.

Related Conditions & MeSH terms

• Solid Tumors

Intervention

Drug:
• Savolitinib
Single dose (together with midazolam) on Study Day 5 after a high fat, high calorie breakfast.
• Midazolam
Single dose (alone) on Study Day 1 and single dose (together with savolitinib) on Study Day 5, both after a high fat, high calorie breakfast.

Locations

Country	Name	City	State
United States	Research Site	Baltimore	Maryland

Sponsors (2)

Lead Sponsor	Collaborator
AstraZeneca	Parexel

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Midazolam: Area under the plasma concentration-time curve from time zero to infinity (AUC) ratio of geometric means of test treatment (midazolam + savolitinib), relative to reference treatment (midazolam alone).	To assess the effect of savolitinib on the PK of midazolam.	Treatment period 1 and 2 (Study Days 1,2, 5 and 6). Midazolam- pre dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose on Study Days 1 and 5. Savolitinib- pre-dose and 1,2, 4, 6, 8, 12 and 24 hours post dose.
Primary	Midazolam: Maximum observed plasma concentration (Cmax) ratio of geometric means of test treatment (midazolam + savolitinib), relative to reference treatment (midazolam alone).	To assess the effect of savolitinib on the PK of midazolam.	Treatment period 1 and 2 (Study Days 1,2, 5 and 6). Midazolam- pre dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose on Study Days 1 and 5. Savolitinib- pre-dose and 1,2, 4, 6, 8, 12 and 24 hours post dose.
Secondary	Midazolam: Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-t)] ratios of geometric means of test treatment (midazolam + savolitinib), relative to reference treatment (midazolam alone).	To describe the PK of midazolam in the presence and absence of savolitinib.	Treatment period 1 and 2 (Study Days 1,2, 5 and 6). Midazolam- pre dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose on Study Days 1 and 5. Savolitinib- pre-dose and 1,2, 4, 6, 8, 12 and 24 hours post dose.
Secondary	Midazolam: Cmax	To describe the PK of midazolam in the presence and absence of savolitinib.	Treatment period 1 and 2 (Study Days 1,2, 5 and 6). Midazolam- pre dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose on Study Days 1 and 5. Savolitinib- pre-dose and 1,2, 4, 6, 8, 12 and 24 hours post dose.
Secondary	Midazolam: [AUC(0-t)]	To describe the PK of midazolam in the presence and absence of savolitinib.	Treatment period 1 and 2 (Study Days 1,2, 5 and 6). Midazolam- pre dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose on Study Days 1 and 5. Savolitinib- pre-dose and 1,2, 4, 6, 8, 12 and 24 hours post dose.
Secondary	Midazolam: Time to reach maximum observed plasma concentration (tmax)	To describe the PK of midazolam in the presence and absence of savolitinib.	Treatment period 1 and 2 (Study Days 1,2, 5 and 6). Midazolam- pre dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose on Study Days 1 and 5. Savolitinib- pre-dose and 1,2, 4, 6, 8, 12 and 24 hours post dose.
Secondary	Midazolam: Half-life associated with terminal slope (?z) of a semi-logarithmic concentration time curve (t½,?z)	To describe the PK of midazolam in the presence and absence of savolitinib.	Treatment period 1 and 2 (Study Days 1,2, 5 and 6). Midazolam- pre dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose on Study Days 1 and 5. Savolitinib- pre-dose and 1,2, 4, 6, 8, 12 and 24 hours post dose.
Secondary	Midazolam: Terminal elimination rate constant (?z)	To describe the PK of midazolam in the presence and absence of savolitinib.	Treatment period 1 and 2 (Study Days 1,2, 5 and 6). Midazolam- pre dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose on Study Days 1 and 5. Savolitinib- pre-dose and 1,2, 4, 6, 8, 12 and 24 hours post dose.
Secondary	Midazolam and savolitinib: Apparent total body clearance of drug from plasma after extravascular administration (CL/F)	To describe the PK of midazolam in the presence and absence of savolitinib.	Treatment period 1 and 2 (Study Days 1,2, 5 and 6). Midazolam- pre dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose on Study Days 1 and 5. Savolitinib- pre-dose and 1,2, 4, 6, 8, 12 and 24 hours post dose.
Secondary	Midazolam and savolitinib: Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)	To describe the PK of midazolam in the presence and absence of savolitinib.	Treatment period 1 and 2 (Study Days 1,2, 5 and 6). Midazolam- pre dose, and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 16 and 24 hours post dose on Study Days 1 and 5. Savolitinib- pre-dose and 1,2, 4, 6, 8, 12 and 24 hours post dose.
Secondary	Number of subjects with adverse events	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day -1, 1, 2, 3, 4, 5, 6, 19
Secondary	Number of subjects with abnormal systolic blood pressure (BP)	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day -1, 1, 2, 5, 6, 19. Vital signs on dosing days will be collected at pre dose, 0.5, 1, 2, 3, 4, 8 and 24 hours post dose.
Secondary	Number of subjects with abnormal diastolic blood pressure (BP)	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day -1, 1, 2, 5, 6, 19. Vital signs on dosing days will be collected at pre dose, 0.5, 1, 2, 3, 4, 8 and 24 hours post dose.
Secondary	Number of subjects with abnormal findings in pulse rate	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day -1, 1, 2, 5, 6, 19. Vital signs on dosing days will be collected at pre dose, 0.5, 1, 2, 3, 4, 8 and 24 hours post dose.
Secondary	Number of subjects with abnormal findings in physical examination	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day -1, 1, 2, 3, 4, 5, 6 and 19
Secondary	Number of subjects with abnormal findings in White blood cell (WBC) count	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day 1, 4, 5 and 19
Secondary	Number of subjects with abnormal findings in Red blood cell (RBC) count	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day 1, 4, 5 and 19
Secondary	Number of subjects with abnormal findings in Hemoglobin (Hb)	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day 1, 4, 5 and 19
Secondary	Number of subjects with abnormal findings in Hematocrit (HCT)	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day 1, 4, 5 and 19
Secondary	Number of subjects with abnormal findings in Mean corpuscular volume (MCV)	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day 1, 4, 5 and 19
Secondary	Number of subjects with abnormal findings in Mean corpuscular hemoglobin (MCH)	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day 1, 4, 5 and 19
Secondary	Number of subjects with abnormal findings in Mean corpuscular hemoglobin concentration (MCHC)	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day 1, 4, 5 and 19
Secondary	Number of subjects with abnormal findings in Neutrophils absolute count	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day 1, 4, 5 and 19
Secondary	Number of subjects with abnormal findings in Monocytes absolute count	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day 1, 4, 5 and 19
Secondary	Number of subjects with abnormal findings in Eosinophils absolute count	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day 1, 4, 5 and 19
Secondary	Number of subjects with abnormal findings in Basophils absolute count	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day 1, 4, 5 and 19
Secondary	Number of subjects with abnormal findings in Platelets	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day 1, 4, 5 and 19
Secondary	Number of subjects with abnormal findings in Reticulocytes absolute count	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day 1, 4, 5 and 19
Secondary	Number of subjects with abnormal findings in sodium	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day 1, 4, 5 and 19
Secondary	Number of subjects with abnormal findings in pottasium	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day 1, 4, 5 and 19
Secondary	Number of subjects with abnormal findings in urea	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day 1, 4, 5 and 19
Secondary	Number of subjects with abnormal findings in creatinine	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day 1, 4, 5 and 19
Secondary	Number of subjects with abnormal findings in albumin	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day 1, 4, 5 and 19
Secondary	Number of subjects with abnormal findings in calcium	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day 1, 4, 5 and 19
Secondary	Number of subjects with abnormal findings in phosphate	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day 1, 4, 5 and 19
Secondary	Number of subjects with abnormal findings in glucose (fasting)	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day 1, 4, 5 and 19
Secondary	Number of subjects with abnormal findings in C-reactive protein (CRP)	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day 1, 4, 5 and 19
Secondary	Number of subjects with abnormal findings in T4	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening
Secondary	Number of subjects with abnormal findings in Thyroid-Stimulating Hormone (TSH)	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening
Secondary	Number of subjects with abnormal findings in Alkaline phosphatase (ALP)	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day 1, 4, 5 and 19
Secondary	Number of subjects with abnormal findings in Alanine aminotransferase (ALT)	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day 1, 4, 5 and 19
Secondary	Number of subjects with abnormal findings in Aspartate aminotransferase (AST)	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day 1, 4, 5 and 19
Secondary	Number of subjects with abnormal findings in Gamma glutamyl transpeptidase (GGT)	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day 1, 4, 5 and 19
Secondary	Number of subjects with abnormal findings in total bilirubin	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day 1, 4, 5 and 19
Secondary	Number of subjects with abnormal findings in unconjugated bilirubin	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day 1, 4, 5 and 19
Secondary	Number of subjects with abnormal findings in urinalysis	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	At screening, Day 1, 4, 5 and 19
Secondary	Number of subjects with abnormal findings in pulse oximetry	To examine the safety and tolerability of midazolam alone and in combination with savolitinib.	Day 1 and 5